Millendo Therapeutics, Inc.
MLND · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.00 | 0.00 | 0.00 |
| FCF Yield | 349.88% | 199.35% | 0.00% | 65.44% |
| EV / EBITDA | -1.67 | 0.20 | 0.44 | -0.81 |
| Quality | ||||
| ROIC | -24.38% | -43.19% | -45.12% | 74.72% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -4.69 | -1.02 | – | -1.25 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 104.92% | 0.00% | -100.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.27 | 0.71 | 0.77 | 0.83 |
| Interest Coverage | -41.83 | -173.17 | -67.93 | 16.30 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |